Premium
Liver and kidney function in patients with Covid‐19 treated with remdesivir
Author(s) -
Laar Sylvia A.,
Boer Mark G. J.,
GombertHandoko Kim B.,
Guchelaar HenkJan,
Zwaveling Juliette
Publication year - 2021
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/bcp.14831
Subject(s) - medicine , renal function , contraindication , alanine transaminase , adverse effect , aspartate transaminase , liver function , population , nephrotoxicity , liver function tests , urology , gastroenterology , kidney , pathology , alkaline phosphatase , biochemistry , chemistry , environmental health , enzyme , alternative medicine
For the treatment of Covid‐19 patients with remdesivir, poor renal and liver function were both exclusion criteria in randomized clinical trials and contraindication for treatment. Also, nephrotoxicity and hepatotoxicity are reported as adverse events. We retrospectively reviewed renal and liver functions of Covid‐19 103 patients who received remdesivir in the 15 days after treatment initiation. Approximately 20% of the patient population met randomized clinical trial exclusion criteria. In total, 11% of the patients had a decrease in estimated glomerular filtration rate >10 mL/min/1.73m 2 . Also, 25 and 35% had increased alanine transaminase and aspartate transaminase levels, respectively. However, serious adverse events were limited. Therefore, based on these preliminary results, contraindications based on kidney and liver function should not be absolute for remdesivir treatment in patients with Covid‐19 if these functions are monitored regularly. A larger patient cohort is warranted to confirm our results.